{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:27:49Z","timestamp":1786703269489,"version":"build-2736575974"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"DOI":"10.1186\/s12902-025-01987-0","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:38:29Z","timestamp":1751416709000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Adrenal venous sampling outcomes with and without mineralocorticoid receptor antagonists in primary aldosteronism"],"prefix":"10.1186","volume":"25","author":[{"given":"Sittikul","family":"Thipbumrung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3007-3951","authenticated-orcid":false,"given":"Worapaka","family":"Manosroi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"issue":"4","key":"1987_CR1","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1210\/clinem\/dgaa952","volume":"106","author":"AF Turcu","year":"2021","unstructured":"Turcu AF, Auchus R. Approach to the patient with primary aldosteronism: utility and limitations of adrenal vein sampling. J Clin Endocrinol Metab. 2021;106(4):1195\u2013208.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"1987_CR2","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1161\/CIRCULATIONAHA.118.033597","volume":"138","author":"JB Byrd","year":"2018","unstructured":"Byrd JB, Turcu AF, Auchus RJ. Primary aldosteronism: practical approach to diagnosis and management. Circulation. 2018;138(8):823\u201335.","journal-title":"Circulation"},{"issue":"2","key":"1987_CR3","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1210\/jc.2018-01299","volume":"104","author":"AT Nanba","year":"2019","unstructured":"Nanba AT, Wannachalee T, Shields JJ, Byrd JB, Rainey WE, Auchus RJ, et al. Adrenal vein sampling lateralization despite mineralocorticoid receptor antagonists exposure in primary aldosteronism. J Clin Endocrinol Metab. 2019;104(2):487\u201392.","journal-title":"J Clin Endocrinol Metab"},{"key":"1987_CR4","unstructured":"Parmar MS, Singh S. Conn syndrome. StatPearls. Treasure Island (FL): StatPearls publishing copyright \u00a9 2023. StatPearls Publishing LLC.; 2023."},{"key":"1987_CR5","unstructured":"Dominguez A, Muppidi V, Gupta S. Hyperaldosteronism. StatPearls. Treasure Island (FL): StatPearls publishing copyright \u00a9 2023. StatPearls Publishing LLC.; 2023."},{"key":"1987_CR6","doi-asserted-by":"crossref","unstructured":"Rossi GP, Auchus RJ, Brown M, Lenders JW, Naruse M, Plouin PF et al. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. Hypertension (Dallas, Tex: 1979). 2014;63(1):151\u2013\u200960.","DOI":"10.1161\/HYPERTENSIONAHA.113.02097"},{"issue":"9","key":"1987_CR7","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1007\/s00270-017-1637-x","volume":"40","author":"KC Ching","year":"2017","unstructured":"Ching KC, Cohen DL, Fraker DL, Trerotola SO. Adrenal vein sampling for primary aldosteronism: A 2-Week protocol for withdrawal of Renin-Stimulating antihypertensives. Cardiovasc Intervent Radiol. 2017;40(9):1367\u201371.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"9","key":"1987_CR8","doi-asserted-by":"publisher","first-page":"953","DOI":"10.4158\/EP-2019-0599","volume":"26","author":"M Ganesh","year":"2020","unstructured":"Ganesh M, Abadin SS, Fogelfeld L. Adrenal vein sampling without discontinuation of mineralocorticoid receptor antagonist therapy. Endocr Pract. 2020;26(9):953\u20139.","journal-title":"Endocr Pract"},{"key":"1987_CR9","doi-asserted-by":"publisher","first-page":"798364","DOI":"10.3389\/fcvm.2021.798364","volume":"8","author":"X Lin","year":"2021","unstructured":"Lin X, Ullah MHE, Wu X, Xu F, Shan SK, Lei LM, et al. Cerebro-Cardiovascular risk, target organ damage, and treatment outcomes in primary aldosteronism. Front Cardiovasc Med. 2021;8:798364.","journal-title":"Front Cardiovasc Med"},{"issue":"6","key":"1987_CR10","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1161\/HYPERTENSIONAHA.124.22721","volume":"81","author":"G Pintus","year":"2024","unstructured":"Pintus G, Seccia TM, Amar L, Azizi M, Riester A, Reincke M, et al. Subtype identification of surgically curable primary aldosteronism during treatment with mineralocorticoid receptor Blockade. Hypertension. 2024;81(6):1391\u20139.","journal-title":"Hypertension"},{"issue":"12","key":"1987_CR11","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.1210\/jc.2014-2788","volume":"99","author":"M Haase","year":"2014","unstructured":"Haase M, Riester A, Kr\u00f6pil P, Hahner S, Degenhart C, Willenberg HS, et al. Outcome of adrenal vein sampling performed during concurrent mineralocorticoid receptor antagonist therapy. J Clin Endocrinol Metab. 2014;99(12):4397\u2013402.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1987_CR12","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1210\/js.2017-00481","volume":"2","author":"Y Shibayama","year":"2018","unstructured":"Shibayama Y, Wada N, Naruse M, Kurihara I, Ito H, Yoneda T, et al. The occurrence of apparent bilateral aldosterone suppression in adrenal vein sampling for primary aldosteronism. J Endocr Soc. 2018;2(5):398\u2013407.","journal-title":"J Endocr Soc"},{"key":"1987_CR13","volume-title":"Guidelines for ATC classification and DDD assignment 2023","author":"WHO Collaborating Centre for Drug Statistics Methodology","year":"2022","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2023. Norway: Oslo; 2022."},{"issue":"9","key":"1987_CR14","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S2213-8587(17)30135-3","volume":"5","author":"TA Williams","year":"2017","unstructured":"Williams TA, Lenders JWM, Mulatero P, Burrello J, Rottenkolber M, Adolf C, et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017;5(9):689\u201399.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"1987_CR15","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3109\/07853890.2013.785234","volume":"45","author":"CT Chao","year":"2013","unstructured":"Chao CT, Wu VC, Kuo CC, Lin YH, Chang CC, Chueh SJ, et al. Diagnosis and management of primary aldosteronism: an updated review. Ann Med. 2013;45(4):375\u201383.","journal-title":"Ann Med"},{"key":"1987_CR16","doi-asserted-by":"crossref","unstructured":"Rossi GP, Ceolotto G, Rossitto G, Maiolino G, Cesari M, Seccia TM. Effects of mineralocorticoid and AT1 receptor antagonism on the Aldosterone-Renin ratio in primary Aldosteronism-the EMIRA study. J Clin Endocrinol Metab. 2020;105(6).","DOI":"10.1210\/clinem\/dgaa080"},{"issue":"4","key":"1987_CR17","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1097\/HJH.0000000000003377","volume":"41","author":"RM Alnazer","year":"2023","unstructured":"Alnazer RM, Veldhuizen GP, de Leeuw PW, Kroon AA. The effect of age, sex and BMI on the aldosterone-to-renin ratio in essential hypertensive individuals. J Hypertens. 2023;41(4):618\u201323.","journal-title":"J Hypertens"},{"issue":"3","key":"1987_CR18","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2215\/CJN.07821109","volume":"5","author":"MR Weir","year":"2010","unstructured":"Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol. 2010;5(3):531\u201348.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1987_CR19","doi-asserted-by":"crossref","unstructured":"Ghazi L, Drawz P. Advances in Understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS Blockade in heart failure and diabetic nephropathy. F1000Res. 2017;6.","DOI":"10.12688\/f1000research.9692.1"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-025-01987-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-025-01987-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-025-01987-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T09:32:43Z","timestamp":1786699963000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12902-025-01987-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1987"],"URL":"https:\/\/doi.org\/10.1186\/s12902-025-01987-0","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"25 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article has been updated.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki and was approved by the Ethical Committee, Chiang Mai University (MED-2566-0153). Informed consent was not obtained as this was a retrospective study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflict of interest.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have nothing to disclose.","order":5,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"165"}}